InfuSystem reports Q2 EPS 12c vs. 3c last year

Reports Q2 revenue $36.0M, consensus $36.14M. CEO Carrie Lachance commented, “We delivered strong Q2 financial results, highlighted by margin expansion, robust cash flow generation and meaningful profitability. Revenue grew 7% to $36M and gross margins expanded by 5.7% to 55.2%. This translated into a 32% increase in Adjusted EBITDA, which rose to $8M. Our EBITDA margin improved by 4.3% to 22.3% and our net income increased by 262%. Cash from operations was $8.8M, more than double prior year results, both for the quarter and year-to-date. These solid results are a testament to our team’s commitment to disciplined execution and continuous process improvement.” “Looking ahead, we are focused on expanding margins and improving profitability. Accordingly, we are raising our full year 2025 outlook for Adjusted EBITDA margin to 20% or higher, an increase of 1.2%. Concurrently, we are revising our 2025 revenue growth outlook to a range of 6%-8%, down from the prior range of 8%-10% to reflect a change in the anticipated ramp-up of Advanced Wound Care and Chemo Mouthpiece…Despite the lower sales forecast, Adjusted EBITDA range has improved due to cost management, product mix and other operational improvements resulting in the higher Adjusted EBITDA margin. As we enter the second half of the year, our mandate remains clear – execute with discipline, deliver profitable growth and drive long-term value creation for our shareholders”.